Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 75 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Follow-Up Questions
Who is the CEO of Septerna Inc?
Dr. Jeffrey Finer is the Chief Executive Officer of Septerna Inc, joining the firm since 2019.
What is the price performance of SEPN stock?
The current price of SEPN is $21.01, it has increased 1.99% in the last trading day.
What are the primary business themes or industries for Septerna Inc?
Septerna Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Septerna Inc market cap?
Septerna Inc's current market cap is $936.8M
Is Septerna Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Septerna Inc, including 2 strong buy, 7 buy, 2 hold, 0 sell, and 2 strong sell
